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Abstract
Background: To assess the feasibility and uptake of a diabetes screening programme; to examine
the effects of invitation to diabetes screening on anxiety, self-rated health and illness perceptions.
Methods: Randomised controlled trial in two general practices in Cambridgeshire. Individuals aged
40–69 without known diabetes were identified as being at high risk of having undiagnosed type 2
diabetes using patient records and a validated risk score (n = 1,280). 355 individuals were
randomised in a 2 to 1 ratio into non-invited (n = 238) and invited (n = 116) groups. A stepwise
screening programme confirmed the presence or absence of diabetes. Six weeks after the last
contact (either test or invitation), a questionnaire was sent to all participants, including non-
attenders and those who were not originally invited. Outcome measures included attendance,
anxiety (short-form Spielberger State Anxiety Inventory-STAI), self-rated health and diabetes
illness perceptions.
Results: 95 people (82% of those invited) attended for the initial capillary blood test. Six individuals
were diagnosed with diabetes. Invited participants were more anxious than those not invited (37.6
vs. 34.1 STAI, p-value = 0.015), and those diagnosed with diabetes were considerably more anxious
than those classified free of diabetes (46.7 vs. 37.0 STAI, p-value = 0.031). Non-attenders had a
higher mean treatment control sub-scale (3.87 vs. 3.56, p-value = 0.016) and a lower mean
emotional representation sub-scale (1.81 vs. 2.68, p-value = 0.001) than attenders. No differences
in the other five illness perception sub-scales or self-rated health were found.
Conclusion: Screening for type 2 diabetes in primary care is feasible but may be associated with
higher levels of short-term anxiety among invited compared with non-invited participants.
Trial registration: ISRCTN99175498
Background
Type 2 diabetes meets many of the criteria for suitability
for screening. It is increasingly common and creates a sub-
stantial burden of suffering and health service use [1].
(However, there is continuing uncertainty concerning fea-
sibility, uptake and the overall benefits and costs, both
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disbenefit to the majority of people who screen negative,
either directly or through false reassurance, may outweigh
significant benefits to the minority whose condition is
detected and treated earlier. Consequently it is important
to quantify adverse effects of screening at the population
level prior to initiation of a programme [3]. However,
such adverse effects are rarely assessed using randomised
trial designs.
Descriptions of screening programmes for diabetes have
highlighted possible harmful effects of misdiagnosis
among screened individuals [4], negative attitudes among
patients diagnosed through screening [5] and a small
reduction in perceived health after a false positive result in
a screening test for gestational diabetes [6]. However, data
from observational studies among screened patients sug-
gest that psychological harms associated with screening
are small and short-lived [7,8]. Furthermore, in a recent
large controlled trial which compared screened and
unscreened individuals, the few significant differences
were not considered clinically important [9].
This study reports results from an individually randomised
controlled trial undertaken during the pilot phase of the
ADDITION trial of a stepwise screening programme for
diabetes [10] (NCT 00237549). We aimed to examine (i)
the feasibility of a stepwise screening programme in gen-
eral practice; (ii) the uptake of the screening programme;
(iii) the effects of the programme on participant's anxiety,
self-rated health and illness perceptions of diabetes.
Methods
This RCT was undertaken as part of the pilot phase of the
ADDITION trial [10]. However, none of the practices or
participants in the randomised trial reported in this paper
were included in the main ADDITION study [9,10]. Two
general practices in Cambridgeshire, East of England, par-
ticipated. Practice A is a rural practice in a market town
near Huntingdon with a list of 7,800 patients. Practice B
has 9,537 patients in central Cambridge. Both practices
serve relatively affluent populations and receive few dep-
rivation payments. Eligible participants were aged 40–69
without known diabetes, identified as being at high risk of
having undiagnosed type 2 diabetes using a score based
on information routinely recorded in electronic patient
records (age, sex, BMI and prescribed medication) [11].
The complete data required to calculate the diabetes risk
score were recorded in the practice computer files for
3,792 of the 5,844 people (65%) who met the inclusion
criteria. We randomly selected 1,280 participants from
this group using SPSS (v.9.0.1) and those falling above a
diabetes risk score threshold of 0.19 comprised the study
sample (n = 355). Using SPSS, the study sample was then
individually randomised in a 2 to 1 ratio into non-invited
(238) and invited (116) groups, to optimise study power
and feasibility. The invited group was further randomised
to receive loss (57) or gain (59) framed invitations by per-
sonal letter [12]. A flow chart of attendance is shown in
Figure 1.
Diabetes screening
Those who attended their screening appointment under-
went a step-wise procedure to confirm the presence or
absence of diabetes. In the first stage, a random capillary
blood sample was taken by the practice nurse and tested
using HemoCue B-Glucose glucometers (HemoCue Ltd.,
Angelholm, Sweden). Participants with a random capil-
lary glucose result ≥ 5.5 mmol/l were classified as screen-
ing-test-positive and were asked to re-attend for a fasting
capillary blood glucose test at a later date. Individuals
whose random capillary glucose result was < 5.5 mmol/l
were classified as not having type 2 diabetes and were
informed of their result. In the second stage, participants
whose fasting capillary glucose result was ≥ 12 mmol/l
were informed that they had type 2 diabetes. Participants
with a fasting result ≤ 5.5 mmol/l were informed that they
did not have diabetes. Those participants with a fasting
glucose of 5.5 – 12 mmol/l were classified as requiring a
further confirmatory 75 g oral glucose tolerance test,
which was undertaken at the same visit. Those whose 2-
hour capillary glucose was ≥ 11.1 mmol/l were informed
that they had type 2 diabetes. Those who tested positive
were informed of the consequences of the diagnosis of
diabetes in a subsequent consultation with their general
practitioner. The thresholds for fasting and 2-hour glucose
in this study were those recommended by the World
Health Organisation in 1999 for diagnosis using capillary
glucose testing [13]. A flow chart of the step-wise screen-
ing procedure is shown in Figure 1.
Six weeks after the last contact (either test or invitation), a
questionnaire assessing anxiety, self-rated health and ill-
ness perceptions was sent to all participants, including
non-attenders and those who were not originally invited.
A freepost return envelope was included, and repeat
duplicate questionnaires were sent to non-responders at 4
and 8 weeks following the initial mailing.
Questionnaire measurements
Anxiety was measured using the short form of the Spiel-
berger State Anxiety Inventory (STAI). This consists of six,
4-point Likert scales, and has been shown to correlate well
(r > 0.9) with the results of the longer questionnaire from
which it was derived [14], which is in turn associated with
indicators of anxiety [15]. The STAI used in this study
measures state (current state of anxiety or mood) rather
than trait (recurring or individual characteristics of anxi-
ety or mood) anxiety [14]. Participants were also asked
about their self-perceived health with a single, 5-pointPage 2 of 9
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Flow chart of participant attendance and outcome of screeningigure 1
Flow chart of participant attendance and outcome of screening.
BMC Public Health 2008, 8:350 http://www.biomedcentral.com/1471-2458/8/350Likert scale (excellent, very good, good, fair, poor), previ-
ously used in a study of screening for gestational diabetes
[6]. Illness perceptions were assessed with the 50-item
diabetes Illness Perception Questionnaire (IPQ). It was
derived from the most accurate measure of illness percep-
tions available at the time [16,17] and has shown good
internal consistency and test-retest reliability in its various
components [18]. The questionnaire was based on Lev-
enthal's self-regulatory model of cognitive psychology,
which predicts how patients form their own personal
models of their disease (illness perceptions) to make
sense of their illness experience and help them form cop-
ing responses [19,20]. The IPQ expands the five basic
components of illness representations [20] into the fol-
lowing sub-components:
1. Identity (whether certain symptoms are associated with
diabetes; e.g. thirst, skin changes)
2. Timeline acute/chronic (e.g. a statement that agrees that
diabetes is chronic would be: "diabetes lasts a long time")
3. Timeline cyclical (e.g. "the symptoms of diabetes come
and go in cycles")
4. Consequences of diabetes (e.g. "Diabetes has serious
financial consequences")
5. Personal control of diabetes (how one's attitude and
behaviour affects diabetes, e.g. "The course of diabetes
depends on the patient")
6. Treatment control (how medical treatment affects dia-
betes, e.g. "Treatment can control diabetes")
7. Emotional representation (what emotions are associ-
ated with diabetes, e.g. "Diabetes makes me feel afraid.")
8. Causes of diabetes (e.g. being overweight, patient's per-
sonality)
Statistical analysis
The primary outcome, STAI, was scaled to have the same
range (20 to 80) as the original longer form. STAI and IPQ
scores were assessed for internal consistency using Cron-
bach's alpha. Unpaired t-tests were used to compare mean
scores between groups for state anxiety, illness representa-
tions and self-reported health. Attendance rates were sum-
marised with exact 95% confidence intervals. Pearson's
chi-squared test was used to compare response rates
between groups. Linear regression was used to assess
whether STAI was associated with baseline characteristics
or other psychological measures. Analyses were com-
pleted using SPSS (version 12.0) and StatXact (version
4.0). All tests were two-sided and assessed at the 5% level
of statistical significance. 140 non-invited and 70 invited
participants responding to the questionnaire (60%
response rate), would have provided 80% power to detect
a five-point difference in mean STAI (SD = 12) between
non-invited and invited arms using a two-sided unpaired
t-test at the 5% level of significance (nQuery version 4.0
software).
This trial was approved by Cambridge LREC (00/071).
Participants provided written consent.
Results
Baseline characteristics for invited and non-invited partic-
ipants are shown in Table 1. Two-thirds were men and
one-third women, reflecting the fact that male sex confers
an increased risk for having undiagnosed type 2 diabetes.
There was no difference in mean age, mean BMI, or the
percentage prescribed anti-hypertensive/steroid medica-
tion between randomised groups.
Screening uptake
95 people attended the initial screening test appointment
(82%, 95% CI: 75% to 89%) out of the 116 patients
invited. Those who attended did not significantly differ
from non-attenders in terms of age, sex, and BMI. How-
ever, attenders were more likely to have been prescribed
antihypertensive or steroid medication (data not shown).
The rate of attendance through the complete step-wise
screening process was 77% (95% CI: 68% to 84%).
Glucose testing (Figure 1)
Of the 95 people who attended for the random capillary
glucose test, 43 (45%) had a glucose ≥ 5.5 mmol/l and
were asked to re-attend for a fasting appointment. 37
(86%) of these people returned, of which 23 (62%) were
Table 1: Baseline characteristics by trial group (invited and non-invited participants). All values are means (SD) unless stated 
otherwise.
Baseline characteristics Invited (n = 116) Non-invited (n = 238)
Age (years) 58.3 (7.3) 58.9 (7.2)
Sex (number (%) male) 76 (65.5%) 149 (62.6%)
BMI (kg/m2) 31.8 (4.5) 31.3 (4.1)
Number (%) prescribed anti-hypertensive medication 42 (36.2%) 91 (38.2%)
Number (%) prescribed steroid medication 10 (8.6%) 6 (2.5%)Page 4 of 9
(page number not for citation purposes)
BMC Public Health 2008, 8:350 http://www.biomedcentral.com/1471-2458/8/350declared free of diabetes, 13 (35%) required a 2-hour oral
glucose tolerance test, and one person had a fasting glu-
cose > 12 mmol/l and was labelled as having type 2 dia-
betes. 5 (39%) of those undergoing a 2h-OGTT test had a
2 h glucose of ≥ 11.1 mmol/l and were labelled as having
diabetes. In total, 6 individuals (5% (95%CI: 2% to 11%)
were given the diagnosis of diabetes as a result of the
screening programme.
Psychological outcomes
The overall response rate to the questionnaire was 68%.
There was no difference in baseline characteristics
between responders and non-responders, and no differ-
ence in the response rate between those invited and not
invited to screening. The STAI six-item anxiety scale
showed a Cronbach's alpha of 0.84, while the IPQ sub-
scales showed a range of internal consistency (0.38 to
0.90). The alpha values were lowest for the timeline cycli-
cal and treatment control sub-scales, with alphas of 0.40
and 0.38 respectively. There was no significant difference
in attendance or anxiety between those invited with loss
and gain frame invitations (Park, P., Simmons, R.K.,
Prevost, A.T., Griffin, S.J., A randomised evaluation of loss
and gain frames in an invitation to screening for type 2 diabetes
– effects on attendance, anxiety and self-rated health. In sub-
mission, Eval Health Prof, 2008), so they were treated as
a single group.
Invited participants were significantly more anxious than
those not invited (Table 2). No statistical difference was
found between attenders and non-attenders (Table 3).
Anxiety was higher among those participants who pro-
gressed further through the screening programme (Figure
2). Those who were eventually diagnosed with diabetes
had the highest STAI values. Individuals with newly diag-
nosed diabetes (positive test result) had a significantly
higher STAI than those who tested negative on the first
RCG.
There were no significant differences between the invited
and non-invited groups for self-rated health and IPQ sub-
scales. Participants who did not attend the first random
glucose test (and therefore did not attend any subsequent
testing) differed significantly from those who did attend
in two sub-scales of their illness perceptions of diabetes
(Table 3). Non-attenders had a higher mean treatment
control sub-scale and a lower mean emotional representa-
tion sub-scale. There were no other differences in psycho-
logical outcomes between attenders and non-attenders,
although the number of non-attenders was small.
Predictors of anxiety
None of the baseline characteristics (age, sex, BMI, pre-
scribed anti-hypertensive/steroid medication) were asso-
ciated with anxiety (data not shown). Of the
psychological outcomes, consequences, emotional repre-
sentations and illness coherence sub-scales of the IPQ
were correlated with raised anxiety. Overall, mean anxiety
level was higher among patients in Practice A than Practice
B, but this was largely due to the fact that all those labelled
with type 2 diabetes were from Practice A (no difference
remained when those with diabetes were removed from
the analysis).
Discussion
This study has shown that it is feasible and acceptable to
screen for type 2 diabetes in two general practices in Cam-
bridgeshire using a risk score to select a high-risk popula-
tion and capillary glucose measurement to test for
diabetes. This finding was replicated in the ADDITION
(Cambridge) controlled trial [9]. There was high attend-
ance for both stages of testing and the methods used to
select participants, invite people for screening and test for
diabetes all proved acceptable and practical. However, rel-
atively few participants were diagnosed, even in this high
risk group. Furthermore, after six weeks, participants who
had been invited to screening exhibited modest differ-
Table 2: Comparison of psychological outcomes between invited and non-invited participants. All values are means (SD).
Invited (n = 77)* Non-invited (n = 168)* p-value from t-test
STAI anxiety (range 20–80) 37.6 (12.2) 34.1 (12.1) 0.015
Self-perceived health; range (1 to 5)** 2.97 (0.86) 2.95 (0.87) 0.82
Illness representation subscales; (range 1 to 5)
- Acute/chronic illness 3.95 (0.48) 4.07 (0.46) 0.07
- Cyclic illness 2.99 (0.42) 2.93 (0.46) 0.64
- Consequences 3.25 (0.47) 3.40 (0.50) 0.08
- Personal consequences 3.67 (0.44) 3.70 (0.45) 0.60
- Treatment control 3.60 (0.41) 3.60 (0.43) 0.87
- Emotional representations 2.58 (0.66) 2.63 (0.75) 0.74
- Illness coherence 3.10 (0.83) 3.05 (0.86) 0.98
* Numbers may vary from those in Figure 1 due to non-response of questionnaires
* *scored 1 = poor 2 = fair 3 = good 4 = very good 5 = excellentPage 5 of 9
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Table 3: Comparison of psychological outcomes between attenders and non-attenders for initial glucose screening. All values are 
means (SD).
Attenders (n = 64)* Non-attenders (n = 13)* p-value from t-test
STAI anxiety (range 20–80) 37.3 (10.9) 39.2 (17.8) 0.77
Self-perceived health; range (1 to 5)** 2.92 (0.86) 3.23 (0.83) 0.24
Illness representation subscales; (range 1 to 5)
- Acute/chronic illness 3.95 (0.48) 3.94 (0.47) 0.90
- Cyclic illness 2.98 (0.41) 3.07 (0.49) 0.90
- Consequences 3.28 (0.47) 3.09 (0.43) 0.22
- Personal consequences 3.66 (0.43) 3.74 (0.55) 0.74
- Treatment control 3.56 (0.41) 3.87 (0.23) 0.016
- Emotional representations 2.68 (0.61) 1.81 (0.45) 0.001
- Illness coherence 3.07 (0.84) 3.29 (0.81) 0.35
* Numbers may vary from those in Figure 1 due to non-response of questionnaires
**Scored 1 = poor 2 = fair 3 = good 4 = very good 5 = excellent
Mean STAI anxiety scores by study group; RCG = random capillary glucoseFigure 2
Mean STAI anxiety scores by study group; RCG = random capillary glucose.
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invited, and those few who were diagnosed with diabetes
were significantly more anxious than those who attended
for the first stage of screening but were classified free of
diabetes.
Attendance
Attenders did not significantly differ from non-attenders,
except that they were more likely to have been prescribed
either antihypertensive or steroid medication. It is possi-
ble that attenders were more likely to have already been
labelled with a chronic disease (such as hypertension) and
had become used to returning regularly to the practice for
monitoring, testing and treatment, and this in turn made
them more motivated or less anxious about attending for
screening for diabetes. Our results for age and sex contrast
with findings from other screening studies where those
who attend for health screening are more likely to be
female [21] and older [22].
Anxiety
Being invited to screening was associated with raised anx-
iety Evidence of causality is strengthened by the apparent
dose-response relationship as participants who pro-
gressed further through the screening process exhibited
higher levels of anxiety compared to those who did not
progress so far or were not invited. There was also a signif-
icant difference in anxiety between test-positives and
those who tested negative at the first stage of screening,
suggesting an adverse effect of the label of diabetes. These
results were gathered by questionnaire at least 6 weeks
after the last appointment, implying that these are
medium-term changes in anxiety rather than an immedi-
ate short-term effect of the invitation or test.
A systematic review of the psychological impact of being
presented with risk information [23] found that anxiety
was not significantly raised in the long term (defined by
the review as more than one month after the information
was presented). Observational studies suggest that there is
little psychological harm associated with a diagnosis of
diabetes by screening [8]. These findings are supported by
data from the ADDITION (Cambridge) controlled trial
[9]. The elevated anxiety found in the present study after
at least 6 weeks for both test-negatives and test-positives is
therefore unexpected. This may be due to the small num-
bers in the present study, the fact that this study was indi-
vidually randomised, as opposed to a cohort study or
controlled trial with participants allocated by cluster, or
the timing of measurement. It is possible that the time-
scale in this study is not sufficiently long-term, and that
people more used to living with diabetes would become
less anxious (response-shift). Qualitative work suggests
that this asymptomatic condition is not considered to be
serious [24]. However, studies of mood and affect in those
with diabetes suggest that the label of diabetes is associ-
ated with depression and anxiety in the long term [25,26],
as the burden of disease and treatment becomes more sali-
ent. The mean anxiety level (STAI score 46.7) in those
with newly diagnosed diabetes is equivalent to a clinical
diagnosis of anxiety according to ICD-10 (STAI score 42
or more) and similar to that found in pregnant women
who have just received an abnormal test result for mater-
nal serum alpha-fetoprotein screening indicating
increased foetal risk of spina bifida and Down's syndrome
[14]. Some degree of anxiety may be unavoidable and
may even have some positive attributes, for example,
increasing motivation for behaviour change. However,
the level of anxiety associated with screening in this study
merits consideration prior to initiation of a screening pro-
gramme. No statistical difference was found between
invited groups after excluding those with diabetes, though
increased anxiety was seen in invitees. As with all screen-
ing programmes, a key challenge is to ensure that any ben-
efit of early diagnosis and treatment for the few outweighs
the population sum of small adverse effects among partic-
ipating individuals.
Since the results in this study would seem to indicate that
being invited for screening is associated with anxiety, it
was important to examine which variables were associ-
ated with greater anxiety. Only the consequences, emo-
tional representations and illness coherence sub-scales
were positively correlated with raised anxiety, which
implies that those with raised anxiety had more negative
feelings about diabetes and its consequences. The provi-
sion of information at the invitation and screening stages
about the potential for controlling diabetes and its com-
plications may therefore be useful in reducing anxiety.
Illness representations
Non-attenders had significantly higher treatment control
and lower negative emotional perceptions than attenders.
This suggests that non-attenders are not sufficiently con-
cerned about the significance of diabetes risk to attend, for
example, they believe that diabetes can be controlled
effectively by treatment and/or do not associate diabetes
with negative emotions. There were no differences in the
results of the IPQ sub-scales between those who were
invited and those not invited to screening, implying that
invitation to screening and its sequelae did not alter the
participants' illness perceptions of diabetes. It is therefore
likely that the observed differences between attenders and
non-attenders were present at baseline and were not
caused by screening, that is to say, the differences in the
IPQ sub-scales were predictors rather than consequences
of attendance. These findings have implications for the
design of future diabetes prevention and invitation mate-
rials concerning screening for type 2 diabetes, as previ-
ously discussed.Page 7 of 9
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This was a fairly small trial with a limited set of measures
yet had the advantage of being population-based and
unlike all previous studies addressing this topic, included
individual randomisation to screening or control group.
Although we included only two GP practices, the study
population was similar to the general population of Eng-
land and Wales for age, sex and BMI as assessed by the
Health Survey for England in 1994 [27], though the par-
ticipants were largely Caucasian. The study population
was not completely representative of the background pop-
ulation of the general practices since participants were
selected for having complete data for calculating the risk
score, and constituted 65% of the possible eligible popu-
lation.
We used capillary glucose measurements for diabetes
screening and diagnosis which are approved by the WHO
[13], but used less frequently in clinical practice than
venous plasma measurements. Further, we did not estab-
lish the diagnosis of type 2 diabetes with two positive
results on separate days, as recommended by the WHO for
participants without known symptoms of diabetes [13].
Given the variability of glucose measures [28], this may
have had a small effect on the accuracy of diagnostic labels
but not the study hypothesis concerning the effects of the
invitation or the disease label.
The questionnaire in this study was administered at only
one time point and the study design relied on randomisa-
tion into invited and non-invited groups to quantify the
effects of invitation to screening on the variables meas-
ured. This approach has the advantage of avoiding the
possible accommodation effect of repeat administration
of questionnaires, an issue that may have limited interpre-
tation of an earlier diabetes screening study [29]. Single
questionnaire testing is also more convenient for partici-
pants, less costly, and associated with higher response
than repeat questionnaires. However, the disadvantage of
single testing is the inability to assess change within indi-
viduals over time. Finally, it is worth considering the ques-
tionnaire measurements themselves. For the illness
perception questionnaire, it is uncertain how applicable a
questionnaire designed for use in a population with a
chronic disease is to a mostly disease-free group. Yet we
demonstrated that beliefs about a condition may be an
important determinant of screening uptake. An early ver-
sion of the IPQ was used and the sub-scales had mixed
internal consistency with Cronbach's alpha values ranging
from 0.38 to 0.90. However, it did not differ substantially
from the current more widely used version [16]. The low
Cronbach's alpha values for some of the psychological
sub-scales do limit our ability to interpret these findings.
For example, the difference in the treatment control sub-
scale between the attenders and non-attenders may be a
chance finding given the low internal consistency of this
measure. The STAI anxiety questionnaire measures state
rather than trait anxiety i.e. the person's anxiety at the
time rather than their general level of anxiety. An assess-
ment of trait anxiety might have been useful in confirming
that raised levels of anxiety were not usual for those in
whom it was observed (and thus were associated with the
screening process). However, a sufficiently large number
of participants were distributed at random into the
groups, and therefore any unknown confounders (includ-
ing trait anxiety) can be assumed to be evenly distributed
between the groups, along with the known confounders
included in Table 1.
Conclusion
This paper describes the first individually-randomised
controlled trial to assess the psychological impact of
screening for diabetes at six weeks. Evidence from this
study suggests that one-off screening in general practice is
feasible and acceptable. However, in contrast to previous
studies, our data imply that being invited to screening
may be associated with increased anxiety six weeks later,
particularly among those given a new diagnosis. While
increased anxiety may not be an entirely negative conse-
quence, it merits further consideration in order to opti-
mise the balance of benefits and harms of any future
screening programme.
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